What’s Your Data Integrity Strategy?
Today’s scientific and technological advancements have increased our ability to detect and correct data integrity risks during the course of a clinical trial.
In fact, these advancements led the FDA to announce an addendum to international Good Clinical Practice (GCP) standards in March of 2018. ICH E6(R2) provides updated regulatory guidance concerning new clinical trial efficiencies in study “design, conduct, oversight, recording, and reporting”. This also means that there are revised expectations for sponsors and CROs when it comes to improving clinical trial data quality.
So how are new data integrity approaches manifesting themselves within the clinical trials industry in 2019? More importantly, which strategies and tactical implementations are leading to successful, actionable insights for sponsors and CROs?
Take this quick survey to receive a report on your data integrity strategy and how you compare to your peers.